IPILIMUMAB, NIVOLUMAB
1525-LCG
Phase 2 small_molecule active
Quick answer
IPILIMUMAB, NIVOLUMAB for type B3 thymoma and thymic carcinoma is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- type B3 thymoma and thymic carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active